- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.08. | Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle | ||
| 06.08. | Sarepta's new CEO Michael Severino faces critical milestones to prove growth | ||
| 06.08. | Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful | ||
| 06.08. | Sanofi asked to change Dupixent ads after Galderma challenge | ||
| 05.08. | AstraZeneca, CSPC to form joint venture for biologics manufacturing | ||
| 05.08. | Alcon survey spots gaps in teen eye care ahead of back-to-school season | ||
| 05.08. | Lilly's obesity pill Foundayo 'disappointed' in Q2, as injectables continue to boom | ||
| 05.08. | Novo CEO has 'no doubt' on eventual share price recovery as Wegovy pill continues to wow | ||
| 05.08. | Gilead's HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability | ||
| 05.08. | 'No discussions' ongoing for AstraZeneca-Bristol Myers merger: Reuters | ||
| 04.08. | Amgen rides Repatha renaissance as cardio wins keep cholesterol med's momentum rolling | ||
| 04.08. | As FDA makes Lipfendra poster child of CNPV pilot, Merck charts long-term path for first PCSK9 pill | ||
| 04.08. | Drugmakers don't have 'duty to innovate', California court rules, backing Gilead in HIV drug litigation | ||
| 04.08. | Pfizer unveils additional $2.5B in planned cost savings through 2029 | ||
| 04.08. | J&J innovative medicine chief Jennifer Taubert to retire, handing reins to North America head | ||
| 04.08. | 'Better every quarter': Bayer CEO stays course on turnaround plan as pharma sales underwhelm in Q2 | ||
| 04.08. | Jazz to withdraw Zepzelca with FDA in second-line small cell lung cancer | ||
| 03.08. | In a first, Otsuka's Voyxact stabilizes IgAN patients' kidney function decline to normal levels | ||
| 03.08. | Curium strikes up to $8B deal for radiopharma rival Lantheus | ||
| 03.08. | Supernus, Indivior merge to create CNS-focused company and expand BD opportunities | ||
| 03.08. | Amgen says patient health data, IP stolen in cybersecurity breach | ||
| 03.08. | Sandoz floats nearly $500M to resolve bulk of lingering US antitrust claims | ||
| 03.08. | Gerresheimer sheds pair of pharma packaging units in deal valued at €1.5B | ||
| 03.08. | After 6-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company | ||
| 03.08. | Editor's Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.